Hyperphosphataemia in patients with Chronic Kidney Disease (CKD) on haemodialysis MedDRA version: 12.0 Level: LLT Classification code 10020711 Term: Hyperphosphataemia
Conditions
Interventions
Product Code: SBR759
Pharmaceutical Form: Powder for oral solution
Current Sponsor code: CSBR759
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1000-
Sponsors
NOVARTIS FARMA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria Patients who have completed a dose-titration study on treatment with SBR759. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Exclusion Criteria History of hypersensitivity to any of the study drug. History of malignancy of any organ system ( other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastasis. Pregnant or nursing (lactating) women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are Women whose career, lifestyle, or sexual orientation precludes intercourse with male partner Women whose partners have been sterilized by vasectomy or other means Using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectibles, combined oral contraceptives, and some intrauterine devices (IUDs), Periodic abstinence(e.g. calendar, ovulation, symptothermal, post ovulation methods are not acceptable. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Primary Objectives: To evaluate long term safety data in patients who have completed a clinical study on SBR759.;Secondary Objective: Key secondary objectives: To evaluate sustained efficacy in patients who have completed a clinical study on SBR759.;Primary end point(s): To evaluate long term safety data in patients who have completed a clinical study on SBR759. | — |
Countries
Belgium, Finland, France, Italy, Sweden, United Kingdom
Outcome results
None listed